Volume is here for a reason, massive $6.8bil future market share predicted, plenty of room
for share price to rise only $30m market cap. 20+ cents is achievable.
To many looking in the review mirror & not the future.
Past does not reflect on the future, Gold stocks were down, now look, back up they go.
CPH has a large range of products & are now also expanding for a larger piece of
the market share purchasing HHI, & developing Halucenex with positive results.
DYOR
- Forums
- ASX - By Stock
- CPH
- Ann: Halucenex Phase II Clinical Trial Update
Ann: Halucenex Phase II Clinical Trial Update, page-10
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CPH (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online